Technical Analysis for SHPG - Shire plc

Grade Last Price % Change Price Change
grade B 164.37 2.26% 3.63
SHPG closed up 2.26 percent on Friday, April 20, 2018, on 2.91 times normal volume.

Earnings due: Apr 26

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical SHPG trend table...

Date Alert Name Type % Chg
Apr 20 Multiple of Ten Bullish Other 0.00%
Apr 19 Shooting Star Candlestick Bearish 2.26%
Apr 19 Lizard Bearish Bearish Day Trade Setup 2.26%
Apr 19 Cup with Handle Other 2.26%
Apr 19 Volume Surge Other 2.26%
Apr 19 Wide Range Bar Range Expansion 2.26%
Apr 19 Multiple of Ten Bearish Other 2.26%
Apr 19 Multiple of Ten Bullish Other 2.26%
Apr 19 Wide Bands Range Expansion 2.26%
Apr 19 Upper Bollinger Band Touch Strength 2.26%

Older signals for SHPG ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). The SP segment offers products for the treatment of attention deficit and hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. It also produces PENTASA and LIALDA/MEZAVANT for the treatment of ulcerative colitis; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, this segment provides FOSRENOL, a phosphate binder for use in end-stage renal failure patients receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. The HGT segment offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. The RM segment provides DERMAGRAFT, a bio-engineered skin substitute that assists in restoring damaged tissue. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. In addition, it is developing various products in the areas of behavioral health, gastrointestinal, HGT, RM, and other therapeutic areas. The company markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. It has operations in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc was founded in 1986 and is headquartered in Dublin, Ireland.
Is SHPG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 190.8738
52 Week Low 122.9082
Average Volume 1,468,229
200-Day Moving Average 147.204
50-Day Moving Average 138.2635
20-Day Moving Average 150.4615
10-Day Moving Average 156.706
Average True Range 5.7029
ADX 42.67
+DI 45.25
-DI 10.12
Chandelier Exit (Long, 3 ATRs ) 160.4013
Chandelier Exit (Short, 3 ATRs ) 142.4787
Upper Bollinger Band 171.5294
Lower Bollinger Band 129.3936
Percent B (%b) 0.83
BandWidth 28.004373
MACD Line 6.6639
MACD Signal Line 5.8468
MACD Histogram 0.8171
Fundamentals Value
Market Cap 48.96 Billion
Num Shares 298 Million
EPS 2.23
Price-to-Earnings (P/E) Ratio 73.71
Price-to-Sales 2.82
Price-to-Book 1.34
PEG Ratio 0.84
Dividend 0.92
Dividend Yield 0.56%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 173.66
Resistance 3 (R3) 173.17 169.58 172.11
Resistance 2 (R2) 169.58 167.22 169.83 171.59
Resistance 1 (R1) 166.98 165.76 168.28 167.47 171.08
Pivot Point 163.39 163.39 164.05 163.64 163.39
Support 1 (S1) 160.79 161.03 162.09 161.28 157.66
Support 2 (S2) 157.20 159.57 157.45 157.15
Support 3 (S3) 154.60 157.20 156.63
Support 4 (S4) 155.09